BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 24122997)

  • 1. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
    Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
    Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
    Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
    Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma.
    Ha SY; Kim SH
    Pathol Res Pract; 2012 Aug; 208(8):462-9. PubMed ID: 22766604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
    Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
    Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of EZH2 in oral squamous cell carcinoma carcinogenesis.
    Zhao L; Yu Y; Wu J; Bai J; Zhao Y; Li C; Sun W; Wang X
    Gene; 2014 Mar; 537(2):197-202. PubMed ID: 24424512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients.
    Wu Z; Wang Q; Wang L; Li G; Liu H; Fan F; Li Z; Li Y; Tu Y
    J Neurol Sci; 2013 Dec; 335(1-2):191-6. PubMed ID: 24139839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyzing simultaneous positive expression of EZH2 and P53 protein to improve predictive value in cervical squamous cell carcinoma.
    Chen SQ; Zhang HM; Li JB; Jiang HY; Fan L; Kong LZ; Yao SZ
    Int J Gynecol Cancer; 2014 Nov; 24(9):1653-8. PubMed ID: 25275664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
    Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
    Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
    Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
    Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-494-3p Induces Cellular Senescence and Enhances Radiosensitivity in Human Oral Squamous Carcinoma Cells.
    Weng JH; Yu CC; Lee YC; Lin CW; Chang WW; Kuo YL
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.
    Yonemitsu Y; Imazeki F; Chiba T; Fukai K; Nagai Y; Miyagi S; Arai M; Aoki R; Miyazaki M; Nakatani Y; Iwama A; Yokosuka O
    Hum Pathol; 2009 Sep; 40(9):1304-11. PubMed ID: 19386347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of expression of enhancer of zeste homolog 2 and 53 in cervical squamous cell carcinoma and intraepithelial neoplasia].
    Zhang H; Chen S; Niu G; Jiang H; Yao S
    Zhonghua Zhong Liu Za Zhi; 2014 Aug; 36(8):597-601. PubMed ID: 25430026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma.
    Wu Y; Zhang L; Zhang L; Wang Y; Li H; Ren X; Wei F; Yu W; Liu T; Wang X; Zhou X; Yu J; Hao X
    Int J Oncol; 2015; 46(6):2586-94. PubMed ID: 25901533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Significance of ALDH1, Bmi1, and OCT4 Expression in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma.
    Rao RS; Raju K L; Augustine D; Patil S
    Cancer Control; 2020; 27(1):1073274820904959. PubMed ID: 32951453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-32 functions as a tumor suppressor and directly targets EZH2 in human oral squamous cell carcinoma.
    Zhang D; Ni Z; Xu X; Xiao J
    Med Sci Monit; 2014 Dec; 20():2527-35. PubMed ID: 25472588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The poor outcome of second primary oral squamous cell carcinoma is attributed to Bmi1 upregulation.
    Hu Q; Wu T; Chen X; Li H; Du Z; Hao Y; Peng J; Tai S; Song M; Cheng B
    Cancer Med; 2018 Apr; 7(4):1056-1069. PubMed ID: 29479858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
    Pietersen AM; Horlings HM; Hauptmann M; Langerød A; Ajouaou A; Cornelissen-Steijger P; Wessels LF; Jonkers J; van de Vijver MJ; van Lohuizen M
    Breast Cancer Res; 2008; 10(6):R109. PubMed ID: 19099573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.
    Svrlanska A; Reichel A; Schilling EM; Scherer M; Stamminger T; Reuter N
    J Virol; 2019 May; 93(9):. PubMed ID: 30814291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
    van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
    Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.
    Martínez-Fernández M; Dueñas M; Feber A; Segovia C; García-Escudero R; Rubio C; López-Calderón FF; Díaz-García C; Villacampa F; Duarte J; Gómez-Rodriguez MJ; Castellano D; Rodriguez-Peralto JL; de la Rosa F; Beck S; Paramio JM
    Oncotarget; 2015 Dec; 6(39):42258-75. PubMed ID: 26517683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.